Literature DB >> 8529288

Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.

L J van Warmerdam1, S Rodenhuis, W W ten Bokkel Huinink, R A Maes, J H Beijnen.   

Abstract

Carboplatin is a chemotherapeutic agent frequently used in the treatment of various malignancies. An individual dosing strategy has been recommended to yield the most optimal exposure, expressed as the area under the concentration-time curve (AUC). The formula developed by Calvert et al. (dose = target-AUC x [GFR + 25]) can be used to achieve this. However, due to the inconvenient [51Cr]-ethylenediamine-tetraacetic acid ([51Cr]-EDTA)-based measurement of the glomerular filtration rate (GFR), its application in the clinic has thus far been limited. Chatelut and co-workers have recently proposed a formula to estimate carboplatin clearance using the serum creatinine concentration. We retrospectively tested the Chatelut equation and the Calvert formula using either the creatinine clearance based on 24-h urine collection or the creatinine clearance based on the formula of Cockcroft and Gault. The latter equations were shown to predict the carboplatin clearance reasonably well, although systematic overprediction and underprediction occurred. However, the formula proposed by Chatelut and co-workers had no significant bias and was precise. It is proposed that this formula be used to calculate the optimal carboplatin dosage after prospective validation has been performed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8529288     DOI: 10.1007/bf00688327

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Dose intensity of carboplatin in combination with cyclophosphamide or ifosfamide.

Authors:  J A Green; K Smith
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

Review 4.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

Review 5.  Advanced ovarian cancer. Carboplatin versus cisplatin.

Authors:  J B Vermorken; W W ten Bokkel Huinink; E A Eisenhauer; G Favalli; D Belpomme; P F Conte; S B Kaye
Journal:  Ann Oncol       Date:  1993       Impact factor: 32.976

6.  Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose.

Authors:  G Daugaard; N Rossing; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 7.  Dose optimisation of carboplatin in adults.

Authors:  A H Calvert
Journal:  Anticancer Res       Date:  1994 Nov-Dec       Impact factor: 2.480

8.  Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.

Authors:  N M Marina; J Rodman; S J Shema; L C Bowman; E Douglass; W Furman; V M Santana; M Hudson; J Wilimas; W Meyer
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

Review 9.  Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity.

Authors:  H Calvert; I Judson; W J van der Vijgh
Journal:  Cancer Surv       Date:  1993

10.  Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.

Authors:  L M Reyno; M J Egorin; R M Canetta; D I Jodrell; K D Swenerton; J L Pater; J N Burroughs; M J Novak; R Sridhara
Journal:  J Clin Oncol       Date:  1993-06       Impact factor: 44.544

View more
  10 in total

Review 1.  Pharmacokinetically guided administration of chemotherapeutic agents.

Authors:  H J van den Bongard; R A Mathôt; J H Beijnen; J H Schellens
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 2.  Pharmacology of anticancer drugs in the elderly population.

Authors:  Hans Wildiers; Martin S Highley; Ernst A de Bruijn; Allan T van Oosterom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics and dose optimisation of carboplatin.

Authors:  S B Duffull; B A Robinson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

4.  Comparison of two methods for carboplatin dosing in children with retinoblastoma.

Authors:  Steven Allen; Matthew W Wilson; Amy Watkins; Catherine Billups; Ibrahim Qaddoumi; Barrett H Haik; Carlos Rodriguez-Galindo
Journal:  Pediatr Blood Cancer       Date:  2010-07-15       Impact factor: 3.167

5.  Multiple resistance modulators combined with carboplatin for resistant malignancies: a pilot study.

Authors:  D J Stewart; R Goel; M C Cripps; S Huan; J Yau; S Verma
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 6.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

7.  Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.

Authors:  V R Nannan Panday; L J van Warmerdam; M T Huizing; W W Ten Bokkel Huinink; J B Vermorken; G Giaccone; C H Veenhof; J H Schellens; J H Beijnen
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

8.  Estimation of glomerular filtration rate in cancer patients.

Authors:  J G Wright; A V Boddy; M Highley; J Fenwick; A McGill; A H Calvert
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

9.  Pharmacokinetic study of carboplatin given on a 5-day intravenous schedule.

Authors:  Y Ando; H Minami; H Saka; M Ando; S Sugiura; S Sakai; K Shimokata
Journal:  Jpn J Cancer Res       Date:  1997-05

10.  Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer.

Authors:  C Kloft; W Siegert; U Jaehde
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.